
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at a new drug called CXD101 to treat cancers that have spread (advanced cancers) and haven’t responded as hoped to previous treatment. This study is for people who have and there is no
available to them.
CXD101 is a drug that blocks substances () in the body called histone deacetylases (pronounced dee-as-et-isle-azes). Cells need these to grow and divide. Blocking them may stop cancer growing. Drugs that block these enzymes are called histone deacetylase inhibitors or HDAC inhibitors.
We know from that CXD101 may be able to stop cancer cells growing. This trial will be the first time CXD101 has been given to people.
The main aims of this trial are to
You may be able to join this trial if
You cannot join this trial if any of these apply
This is a phase 1 trial . Everyone taking part will have CXD101. The first few people will have a low dose of CXD101. If they don’t have any serious side effects, the next few people will have a higher dose. And so on, until they find the best dose to give. This is called a dose escalation study.
While taking CXD101 you will continue to have the same dose you started on.
When the team find the highest dose of CXD101, they will ask about another 20 people to join the trial. This will bring the total number of people they expect to join to between 25 and 40.
If you have a , the researcher will take a small piece of your cancer tissue (
) to check for a substance called HR23B. You must agree to this before you can join this part of the trial.
CXD101 is a capsule that you take twice a day for 5 days. This is then repeated every 3 weeks. You cannot eat for at least 2 hours before taking the capsules and you must wait at least 1 hour afterwards before eating. Your doctor will tell how many capsules to take and when to take them.
You can continue treatment with CXD101 as long as it is helping you and the side effects aren’t too bad.
If you agree to take part in this trial, the researchers will ask for a sample of your cancer that was removed when you had surgery or a previous .
They may ask for another sample of your cancer tissue during the trial. If you don’t want to give this sample, you don’t have to. You can still take part in the study.
They will also ask for some extra blood samples to find out what happens to CXD101 in the body.
You see the doctor to have some tests before taking part in this trial. These tests include
During treatment you see the doctor to have the same tests
Every 6 weeks you have a CT scan or MRI scan.
After you finish treatment, your doctor will tell how often they want to see you.
This is the first time CXD101 has been tested in people so there may be side effects we don’t know about yet. The side effects may include
Your doctor will talk to you about all the possible side effects before you agree to take part in the trial.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor M Middleton
Celleron Therapeutics Ltd
Experimental Cancer Medicine Centre (ECMC)
Oxford University Hospitals NHS Trust
Freephone 0808 800 4040
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.